U.S., Nov. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07230249) titled 'Telegram Messenger Support for Smoking Cessation After Heart Attack' on Nov. 13.
Brief Summary: This randomized controlled trial will evaluate whether a 6-month behavioral intervention delivered via Telegram messenger increases smoking cessation rates in patients after myocardial infarction (MI).
Adult smokers hospitalized with acute MI who regularly use Telegram will be randomly assigned to either:
* INTERVENTION GROUP: Standard care plus a 6-month Telegram chatbot program providing personalized motivational messages, cognitive-behavioral techniques for craving management, and relapse prevention support.
* CONTROL GROUP: Standar...